The monoclonal antibodies belimumab and anifrolumab are both approved for the treatment of systemic lupus erythematosus (SLE). Their response is considered to be highly effective. The point at which they should be used in therapy was discussed on the basis of two case studies at the congress of the German Society for Internal Medicine (DGIM).
This content is machine-translated. Please contact us if you need professional translation services.
Publikation
- InFo RHEUMATOLOGIE
